Wave Life Sciences (NASDAQ:WVE) Earns Buy Rating from Analysts at Jefferies Financial Group

Jefferies Financial Group began coverage on shares of Wave Life Sciences (NASDAQ:WVE) in a research report released on Tuesday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $26.00 price target on the stock.

WVE has been the subject of several other reports. B. Riley raised their target price on shares of Wave Life Sciences from $19.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, November 4th. HC Wainwright reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Wave Life Sciences in a research report on Wednesday, November 13th. Truist Financial boosted their target price on Wave Life Sciences from $17.00 to $36.00 and gave the stock a “buy” rating in a report on Tuesday, November 12th. Mizuho lifted their price objective on shares of Wave Life Sciences from $19.00 to $22.00 and gave the stock an “outperform” rating in a research report on Thursday, November 21st. Finally, StockNews.com downgraded shares of Wave Life Sciences from a “hold” rating to a “sell” rating in a report on Wednesday, November 13th. Two investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $22.60.

Wave Life Sciences Trading Down 0.4 %

Shares of WVE opened at $10.56 on Tuesday. The company’s fifty day simple moving average is $11.85 and its 200 day simple moving average is $11.01. Wave Life Sciences has a 1-year low of $4.25 and a 1-year high of $16.74. The company has a market cap of $1.61 billion, a price-to-earnings ratio of -9.51 and a beta of -1.09.

Hedge Funds Weigh In On Wave Life Sciences

A number of institutional investors have recently modified their holdings of WVE. Charles Schwab Investment Management Inc. grew its holdings in shares of Wave Life Sciences by 209.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 844,617 shares of the company’s stock valued at $6,926,000 after acquiring an additional 571,345 shares in the last quarter. FMR LLC raised its holdings in Wave Life Sciences by 174.5% during the 3rd quarter. FMR LLC now owns 1,540,190 shares of the company’s stock valued at $12,630,000 after acquiring an additional 979,110 shares during the period. Maven Securities LTD bought a new stake in Wave Life Sciences during the 3rd quarter valued at $6,970,000. Privium Fund Management B.V. purchased a new stake in shares of Wave Life Sciences during the third quarter worth $400,000. Finally, Barclays PLC boosted its holdings in shares of Wave Life Sciences by 171.1% in the third quarter. Barclays PLC now owns 159,241 shares of the company’s stock worth $1,307,000 after acquiring an additional 100,498 shares during the period. 89.73% of the stock is owned by institutional investors and hedge funds.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.